EATON
5.7.2022 11:02:09 CEST | Business Wire | Press release
Intelligent power management company Eaton today announced its involvement in a pan-European research and innovation project to deliver the integrated technologies and business models needed to support mass deployment of electric vehicle charging infrastructure.
Supported by the European Union’s Horizon Europe Research and Innovation program, the €9.87M ($10.41M) project will span four years to March 2026, its scope covering the entire electric vehicle charging value chain. The FLOW project consortium, which includes 24 external partners and six leading universities across Europe, will be led by the Fundació Institut De Recerca En Energia De Catalunya .
Eaton’s role in the consortium will involve further developing electric vehicle charging technologies, as well as demonstrating electric vehicle charging solutions, based on experience advancing its Buildings as a Grid approach to uniting the power needs of buildings and electric vehicles with on-site renewable energy generation.
The research and innovation focus will extend across vehicle-to-grid (V2G) and vehicle-to-everything (V2X) capabilities that enable more system flexibility; DC-DC charging (direct current to direct current) that yields both power quality and control benefits; and further work on Eaton’s proprietary Buildings as a Grid Energy Management System that supports forecasting, optimization, and other essential services. To combine the various technologies into a complete solution, several Eaton business units will collaborate on the project—including the pan-European Eaton Research Labs team and the Eaton Center for Intelligent Power in Dublin, Ireland.
Stefan Costea, regional technology manager, Eaton Research Labs, said: “As electric vehicles grow in popularity across Europe, a comprehensive range of fully integrated charging technologies is urgently needed to support mass deployment and enable valuable new services. As a key partner in the FLOW project, we’re thrilled to be developing optimal solutions for electric vehicle charging, V2G, V2X, and energy management. We will demonstrate these technologies at three test labs—at the Eaton European Innovation Center in Prague, at University College Dublin , and at the Fundació Institut De Recerca En Energia De Catalunya, in Barcelona. Additionally, we will be supporting large scale technology demonstrations in Rome and Copenhagen with our energy management systems.”
For the demonstrations in Prague and Barcelona, Eaton will be collaborating closely with Heliox , a market leader in fast charging solutions. University College Dublin and nearby Maynooth University will work with Eaton in Ireland, while RWTH Aachen University , in Germany, will partner with Eaton in Prague on a techno-economic analysis of electric vehicle charging infrastructure use cases. In Rome and Copenhagen, Eaton will collaborate on energy management system interoperability with companies well-known for transmission and distribution: ENEL , Terna , and Areti, in addition to partners at Ricerca Sul Sistema Energetico and the Technical University of Denmark .
Tim Darkes, President, Corporate and Electrical, EMEA, Eaton, explained the context for Eaton’s involvement in the FLOW consortium, saying: “Our work on integrating charging infrastructure into buildings is supporting the rapid move to electric vehicles as part of the energy transition and we’re very proud to be investing heavily in the people, technologies, and programs to accelerate the global drive towards a low-carbon future.”
Jörgen von Bodenhausen, senior manager, Government Programs, Eaton, also added: “We continually seek out opportunities to combine our global scale and expertise with that of world-class industrial and academic partners, thus magnifying our own innovation efforts. From building-in energy management, to DC-DC charging, our work on the FLOW project will help pioneer new solutions to accelerate the commercialization and mass deployment of electric vehicle charging infrastructure and create whole new value propositions for both companies and customers.”
About Eaton
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.
Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com . Follow us on Twitter and LinkedIn .
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005048/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom